title: Improvement in clinical condition and thymus morphologic features associated with growth hormone treatment of immunodeficient dwarf dogs.
abstract: Immunodeficient dwarfism in Weimaraner dogs was characterized by failure to grow, emaciation, growth hormone (GH) deficiency, decreased lymphocyte blastogenic responsiveness to mitogens, lack of thymus cortex, and recurrent infections usually resulting in death. Affected pups did not respond to conventional supportive therapy, but did respond to treatment with thymosin fraction 5. Response to therapy with bovine GH was monitored by clinical observation, histopathologic examination of thymic biopsy material, lymphocyte blastogenic responsiveness to nonspecific mitogens, and radioimmunoassay of thymosin alpha 1 concentration in the serum. Growth hormone therapy (0.1 mg/kg of body weight/dose, 14 doses) during a 1-month period in 2 immunodeficient dwarf pups resulted in clinical improvement and a marked increase in the thickness and cellularity of the cortex of the thymus. Immunodeficient dwarf pups were not deficient in serum thymosin alpha 1 before GH therapy. Growth hormone therapy was not associated with a consistent increase in serum thymosin alpha 1 concentration or lymphocyte blastogenic responsiveness to mitogens.
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004392:Dwarfism / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008213:Lymphocyte Activation / Q000187:drug effects; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives / Q000097:blood; D013950:Thymus Gland / Q000187:drug effects* / Q000473:pathology
chemical_list: D013947:Thymosin; D013006:Growth Hormone; D000077596:Thymalfasin